Segall Bryant & Hamill LLC Sells 22,416 Shares of Vericel Corporation (NASDAQ:VCEL)

Segall Bryant & Hamill LLC lessened its stake in Vericel Corporation (NASDAQ:VCEL - Free Report) by 23.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,910 shares of the biotechnology company's stock after selling 22,416 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.15% of Vericel worth $3,342,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Victory Capital Management Inc. boosted its stake in shares of Vericel by 2.6% in the 1st quarter. Victory Capital Management Inc. now owns 593,933 shares of the biotechnology company's stock valued at $26,501,000 after purchasing an additional 15,221 shares during the last quarter. Kornitzer Capital Management Inc. KS boosted its stake in shares of Vericel by 73.3% in the 1st quarter. Kornitzer Capital Management Inc. KS now owns 20,800 shares of the biotechnology company's stock valued at $928,000 after purchasing an additional 8,800 shares during the last quarter. TimesSquare Capital Management LLC boosted its stake in shares of Vericel by 3.2% in the 1st quarter. TimesSquare Capital Management LLC now owns 652,465 shares of the biotechnology company's stock valued at $29,113,000 after purchasing an additional 20,305 shares during the last quarter. New York State Common Retirement Fund boosted its stake in shares of Vericel by 0.9% in the 1st quarter. New York State Common Retirement Fund now owns 862,331 shares of the biotechnology company's stock valued at $38,477,000 after purchasing an additional 7,429 shares during the last quarter. Finally, Mutual of America Capital Management LLC boosted its stake in shares of Vericel by 5.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 158,930 shares of the biotechnology company's stock valued at $7,091,000 after purchasing an additional 8,789 shares during the last quarter.

Vericel Price Performance

VCEL traded down $0.92 during trading on Friday, reaching $35.34. The company had a trading volume of 545,056 shares, compared to its average volume of 427,426. Vericel Corporation has a 12 month low of $35.18 and a 12 month high of $63.00. The business's fifty day moving average price is $41.54 and its 200 day moving average price is $46.90. The company has a market cap of $1.78 billion, a P/E ratio of 1,178.39 and a beta of 1.32.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.14). The company had revenue of $52.60 million during the quarter, compared to the consensus estimate of $53.86 million. Vericel had a net margin of 1.25% and a return on equity of 1.09%. The business's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.08) EPS. As a group, sell-side analysts predict that Vericel Corporation will post 0.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on VCEL. Stephens restated an "overweight" rating and set a $67.00 price objective on shares of Vericel in a report on Monday, June 16th. Truist Financial decreased their price objective on shares of Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a report on Friday, April 11th. Finally, Wall Street Zen cut shares of Vericel from a "hold" rating to a "sell" rating in a report on Monday, May 12th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat, Vericel has a consensus rating of "Moderate Buy" and a consensus price target of $61.14.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.